文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

按需与常规雾化乙酰半胱氨酸联合沙丁胺醇对有创通气ICU患者无呼吸机天数的影响:一项随机临床试验

Effect of On-Demand vs Routine Nebulization of Acetylcysteine With Salbutamol on Ventilator-Free Days in Intensive Care Unit Patients Receiving Invasive Ventilation: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2018-01-01
一句话结论在预期24小时内不能拔管的ICU有创通气患者中,按需雾化乙酰半胱氨酸联合沙丁胺醇的无呼吸机天数不劣于常规雾化,且不良事件更少。

该随机临床试验在荷兰7个ICU纳入922例预期需要有创通气超过24小时的成人患者,比较按需雾化(根据严格临床指征使用乙酰半胱氨酸或沙丁胺醇,n=471)与常规雾化(每6小时雾化乙酰半胱氨酸联合沙丁胺醇直至有创通气结束,n=473)。主要终点为第28天无呼吸机天数,非劣效界值为-0.5天。结果显示按需组中位无呼吸机天数为21天(IQR 0-26),常规组为20天(IQR 0-26),单侧95%CI为-0.00003至∞,达到非劣效。两组住院时间、死亡率及肺部并发症比例无显著差异;常规雾化组不良事件更频繁(13.8% vs 29.3%),主要为快速性心律失常(12.5% vs 25.9%)和躁动(0.2% vs 4.3%)。作者认为按需雾化可能是常规雾化的合理替代方案。

要点

  • 在预期24小时内不能拔管的ICU有创通气患者中,按需雾化乙酰半胱氨酸联合沙丁胺醇第28天无呼吸机天数不劣于常规雾化(中位21天 vs 20天,单侧95%CI -0.00003至∞,非劣效界值-0.5天)。
  • 常规雾化组不良事件发生率显著高于按需组(29.3% vs 13.8%,差异-15.5%,95%CI -20.7%至-10.3%,P<.001)。
  • 常规雾化组快速性心律失常发生率显著高于按需组(25.9% vs 12.5%,差异-13.4%,95%CI -18.4%至-8.4%,P<.001)。
  • 常规雾化组躁动发生率显著高于按需组(4.3% vs 0.2%,差异-4.1%,95%CI -5.9%至-2.2%,P<.001)。
  • 两组住院时间、死亡率及肺部并发症比例无显著差异。

适用人群与场景

  • 荷兰7个ICU的成人患者,预期需要有创通气超过24小时。

诊断标准与关键阈值

  • 非劣效界值为组间无呼吸机天数差值-0.5天。

处置流程与药物剂量

  • 按需组:根据严格临床指征雾化乙酰半胱氨酸或沙丁胺醇(n=471)。
  • 常规组:每6小时雾化乙酰半胱氨酸联合沙丁胺醇,直至有创通气结束(n=473)。

研究设计与关键结果

  • 随机临床试验,纳入922例患者(女性34%,中位年龄66岁,IQR 54-75岁),在荷兰7个ICU进行,按需组n=471,常规组n=473。
  • 主要终点第28天无呼吸机天数:按需组中位21天(IQR 0-26)vs 常规组中位20天(IQR 0-26),单侧95%CI -0.00003至∞,达到非劣效。
  • 两组住院时间、死亡率及肺部并发症比例无显著差异。
  • 不良事件:常规组29.3% vs 按需组13.8%(差异-15.5%,95%CI -20.7%至-10.3%,P<.001),常规组更频繁。
  • 快速性心律失常:常规组25.9% vs 按需组12.5%(差异-13.4%,95%CI -18.4%至-8.4%,P<.001)。
  • 躁动:常规组4.3% vs 按需组0.2%(差异-4.1%,95%CI -5.9%至-2.2%,P<.001)。

证据类型、等级与局限

  • 证据类型:随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在预期24小时内不能拔管的ICU有创通气患者中,按需雾化可能是常规雾化的合理替代方案。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: It remains uncertain whether nebulization of mucolytics with bronchodilators should be applied for clinical indication or preventively in intensive care unit (ICU) patients receiving invasive ventilation.

OBJECTIVE: To determine if a strategy that uses nebulization for clinical indication (on-demand) is noninferior to one that uses preventive (routine) nebulization.

DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial enrolling adult patients expected to need invasive ventilation for more than 24 hours at 7 ICUs in the Netherlands.

INTERVENTIONS: On-demand nebulization of acetylcysteine or salbutamol (based on strict clinical indications, n = 471) or routine nebulization of acetylcysteine with salbutamol (every 6 hours until end of invasive ventilation, n = 473).

MAIN OUTCOMES AND MEASURES: The primary outcome was the number of ventilator-free days at day 28, with a noninferiority margin for a difference between groups of -0.5 days. Secondary outcomes included length of stay, mortality rates, occurrence of pulmonary complications, and adverse events.

RESULTS: Nine hundred twenty-two patients (34% women; median age, 66 (interquartile range [IQR], 54-75 years) were enrolled and completed follow-up. At 28 days, patients in the on-demand group had a median 21 (IQR, 0-26) ventilator-free days, and patients in the routine group had a median 20 (IQR, 0-26) ventilator-free days (1-sided 95% CI, -0.00003 to ∞). There was no significant difference in length of stay or mortality, or in the proportion of patients developing pulmonary complications, between the 2 groups. Adverse events (13.8% vs 29.3%; difference, -15.5% [95% CI, -20.7% to -10.3%]; P < .001) were more frequent with routine nebulization and mainly related to tachyarrhythmia (12.5% vs 25.9%; difference, -13.4% [95% CI, -18.4% to -8.4%]; P < .001) and agitation (0.2% vs 4.3%; difference, -4.1% [95% CI, -5.9% to -2.2%]; P < .001).

CONCLUSIONS AND RELEVANCE: Among ICU patients receiving invasive ventilation who were expected to not be extubated within 24 hours, on-demand compared with routine nebulization of acetylcysteine with salbutamol did not result in an inferior number of ventilator-free days. On-demand nebulization may be a reasonable alternative to routine nebulization.

TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02159196.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. van Meenen DMP, van der Hoeven SM, Binnekade JM, et al. Effect of On-Demand vs Routine Nebulization of Acetylcysteine With Salbutamol on Ventilator-Free Days in Intensive Care Unit Patients Receiving Invasive Ventilation: A Randomized Clinical Trial. JAMA. 2018. PMID: 29486489. doi:10.1001/jama.2018.0949

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。